Turalio, also known as pexidartinib, has a safety profile that includes risks of liver damage and deep vein thrombosis (DVT) and pulmonary embolism (PE) [1].
What liver problems can Turalio cause?
Turalio can cause serious liver damage, including drug-induced liver injury, which can be fatal [1]. Patients taking Turalio are monitored with liver function tests [1].
What are the risks of blood clots with Turalio?
Turalio is associated with an increased risk of DVT and PE, which can be fatal [1]. Signs of these conditions include swelling, pain, or warmth in one leg, or shortness of breath [1].
Are there other side effects of Turalio?
Other side effects reported with Turalio include fatigue, nausea, diarrhea, vomiting, shortness of breath, abdominal pain, decreased appetite, weight loss, and rash [1].
How is Turalio used?
Turalio is a kinase inhibitor used to treat adults with symptomatic tenosynovial giant cell tumor (TGCT) that is unresectable or associated with the morbidity and mortality that would prevent major surgery [1].
When did Turalio receive FDA approval?
Turalio was approved by the U.S. Food and Drug Administration (FDA) in November 2019 [1].